<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01022801</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-047</org_study_id>
    <nct_id>NCT01022801</nct_id>
  </id_info>
  <brief_title>A Phase II Dose Response Study in Japan in Chronic Hepatitis B</brief_title>
  <official_title>A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) vs Lamivudine in Adults With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the dose response of entecavir in Japanese patients as measured by HBV DNA
      levels by PCR (log10 copies/mL) at Week 22
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in HBV DNA levels as measured by by PCR (log10 copies/mL)</measure>
    <time_frame>at Week 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinical adverse events and discontinuations due to adverse events in each entecavir group in comparison to lamivudine</measure>
    <time_frame>Through Week 24 (end of dosing) plus 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities in each entecavir group in comparison to lamivudine</measure>
    <time_frame>Through Week 24 (end of dosing) plus 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA as measured by PCR (log10 copies/mL) at Week 22 [to demonstrate non-inferiority of at least one dose of entecavir as compared with lamivudine]</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment group who achieve HBV DNA reduced by ≥2 log10 and/or below the limit of quantification (LOQ) (&lt;400 copies/mL) as measured by PCR assay</measure>
    <time_frame>Week 12, Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment group who achieve HBV DNA below the limit of detection (0.7 MEq/mL) of the Quantiplex branched DNA hybridization assay (Quantiplex assay)</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment group who achieve normalization of ALT (ALT &lt;1.25 x UKN)</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment group who achieve loss of HBeAg at Week 22 among HBeAg-positive subjects at baseline</measure>
    <time_frame>Baseline, Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each treatment group who achieve seroconversion at Week 22 among of HBeAg-positive subjects at baseline</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HBeAg-positive subjects at baseline who achieve responder status (defined as: HBV DNA &lt;0.7 MEq/mL by the Quantiplex assay; loss of HBeAg and normal serum ALT)</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of HBeAg-negative subjects at baseline who achieve responder status (defined as HBV DNA &lt;0.7 MEq/mL by the Quantiplex assay and normal serum ALT)</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of genotypic resistance of HBV isolates in subjects who have a ε 1 log10 increase in HBV DNA as measured by PCR assay after achieving the lowest value while on study drug</measure>
    <time_frame>Through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of HBV isolates (genotypes A, B, C etc) at baseline compared to response</measure>
    <time_frame>Week 22</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entecavir (0.01 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir (0.1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir (0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks</description>
    <arm_group_label>Entecavir (0.01 mg)</arm_group_label>
    <arm_group_label>Entecavir (0.1 mg)</arm_group_label>
    <arm_group_label>Entecavir (0.5 mg)</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>BMS-200475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive for HBsAg OR, negative for IgM core antibody and confirmation of chronic
             hepatitis B on liver biopsy,

          -  Positive for HBeAg OR negative for HBeAg with positive HBeAb,

          -  Documented HBV Viremia on 2 or more occasions: Viremia on sample drawn AND HBV DNA of
             ≥ 40 MEq/mL by Quantiplex assay at the screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2009</study_first_submitted>
  <study_first_submitted_qc>November 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2009</study_first_posted>
  <disposition_first_submitted>January 29, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2010</disposition_first_posted>
  <last_update_submitted>January 29, 2010</last_update_submitted>
  <last_update_submitted_qc>January 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

